Thursday, February 25, 2016 11:55:25 AM
February 25, 2016 11:42 AM EST
STONY BROOK, NY -- (Marketwired) -- 02/25/16 -- Applied DNA Sciences, Inc. (NASDAQ: APDN) (NASDAQ: APDNW) (Twitter: @APDN), a provider of DNA-based supply chain, anti-counterfeiting and anti-theft technology, product genotyping and product authentication solutions, has introduced its SigNature® DNA marker into new pharmaceutical-grade and packaging inks suitable for tablet and packaging marking, in partnership with Nissha Printing Company ("Nissha") and Kishu Giken Kogyo Co.,Ltd. ("KGK"). From February 24-26, 2016, SigNature DNA ink and printing solutions will be presented at Medical Japan Expo in Osaka.
Powered by unique botanical-based SigNature DNA, these inks allow for seamless marking at the point-of-manufacture, ensuring that original raw materials or ingredients used to produce pharmaceuticals are fully protected and traceable to point-of-sale. APDN has completed trials with Nissha and KGK partners, proving that unique SigNature DNA marks can be authenticated on the pharmaceutical tablet and packaging materials. The technology satisfies the principles established by FDA Guidelines for inclusion in pharmaceutics and is equally applicable to food and cosmetic products.
APDN can also DNA-mark other elements of a finished product including bulk Active Pharmaceutical Ingredient (API), cellulosic excipients (bulk fillers) that are used in almost all drug tablets and the commercial binders and enteric coatings that hold prescription and Over-the-Counter (OTC) drug tablets together. This unique, multi-factor identification enables verification of its authenticity at any point in the supply chain.
Countries around the world have accelerated their adoption of drug quality regulations in the effort to ensure product integrity and protect patient safety. Regulations covering more than 75% of the global medicine supply by 2018 include packaging standards from Japan's Ministry of Health, Labor and Welfare and directives from the U.S. FDA's Title II of the Drug Supply Chain Security Act. Companies acting now can benefit from SigNature DNA solutions that forensically backstop pharmaceutical traceability.
"The scalability of SigNature DNA for pharmaceuticals solves many supply chain challenges as recently highlighted in Scientific American*. Many of our clients that are using SigNature DNA know that forensic tagging and authentication will protect them from the risk of legal liability and product recall while maintaining profitability and market differentiation," stated Dr. James A. Hayward, President and CEO, APDN.
* For more information please see article "Authentic Drugs Tagged with Plant DNA Could Help Snare Fake Meds" published in Scientific American on January 12, 2016.
Recent APDN News
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/04/2024 10:18:33 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/12/2024 09:25:36 PM
- Form D - Notice of Exempt Offering of Securities • Edgar (US Regulatory) • 02/12/2024 09:09:17 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/08/2024 09:05:22 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/08/2024 09:01:31 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 02/01/2024 09:05:28 PM
- Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend] • Edgar (US Regulatory) • 01/26/2024 09:24:06 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 01/10/2024 10:16:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 12:00:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/05/2024 09:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/07/2023 09:05:23 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 12/07/2023 09:01:50 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/06/2023 09:05:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/07/2023 10:09:34 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/07/2023 10:02:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/20/2023 08:05:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/10/2023 08:05:45 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/10/2023 08:01:59 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/01/2023 08:02:12 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/13/2023 09:04:44 PM
FEATURED Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • May 7, 2024 8:51 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM